Comparative Pharmacology
Head-to-head clinical analysis: CO GESIC versus DARVOCET A500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CO GESIC versus DARVOCET A500.
CO-GESIC vs DARVOCET A500
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CO-GESIC (hydrocodone/acetaminophen) is a combination analgesic. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and elevating pain threshold.
Combination analgesic: acetaminophen inhibits cyclooxygenase (COX) and modulates endocannabinoid system; propoxyphene is a mu-opioid receptor agonist.
1-2 tablets (hydrocodone 5 mg/acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.
One tablet (500 mg acetaminophen, 100 mg propoxyphene napsylate) orally every 4 hours as needed for pain; maximum 6 tablets per day.
None Documented
None Documented
Terminal elimination half-life is approximately 2–4 hours in adults with normal renal function; prolonged in renal impairment.
Propoxyphene: 6-12 hours (terminal, prolonged in elderly, hepatic impairment, or overdose). Acetaminophen: 2-3 hours (terminal, prolonged in hepatic impairment or overdose).
Primarily renal (60–70% as unchanged drug and metabolites); minor biliary/fecal excretion (<5%).
Propoxyphene: ~20-25% renal as unchanged drug, ~35% as norpropoxyphene, ~20% biliary/fecal. Acetaminophen: ~2-4% renal unchanged, ~85% as glucuronide and sulfate conjugates, ~5% as cysteine and mercapturate conjugates.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination